UPLOAD Filing
Rani Therapeutics Holdings, Inc.
Date: Aug. 12, 2025 · CIK: 0001856725 · Accession: 0000000000-25-008450
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289424
Letter
Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 Filed August 8, 2025 File No. 333-289424 Dear Talat Imran:
August 12, 2025
Talat Imran Chief Executive Officer Rani Therapeutics Holdings, Inc. 2051 Ringwood Avenue San Jose, California 95131
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John T. McKenna
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 12, 2025 Talat Imran Chief Executive Officer Rani Therapeutics Holdings, Inc. 2051 Ringwood Avenue San Jose, California 95131 Re: Rani Therapeutics Holdings, Inc. Registration Statement on Form S-3 Filed August 8, 2025 File No. 333-289424 Dear Talat Imran: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John T. McKenna </TEXT> </DOCUMENT>